L-lizine aescinat (diaminohexanoic acid) ampoules 0.1% 5 ml. №10

Description

L-lizine Composition
active substance: escin salt of 2,6-diaminohexanoic acid;

1 ml of solution contains escin salt of 2,6-diaminohexanoic acid, in terms of 100% substance 1.0 mg;

excipients: ethanol 96%, propylene glycol, water for injection.

L-lizine Dosage form

Injection.

Basic physical and chemical properties: clear, colorless liquid.

Pharmacotherapeutic group. Vasoprotectors. Capillary stabilizing agents. Other capillary stabilizing agents. ATX code С05С Х.

L-lizine Pharmacological properties

Pharmacodynamics

The drug has anti-inflammatory, decongestant and analgesic effects. Escin reduces the activity of lysosomal hydrolases, which prevents the breakdown of mucopolysaccharides in the walls of capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has antiexudative (decongestant), anti-inflammatory and analgesic effects. The drug increases vascular tone, has moderate immunocorrective and hypoglycemic effects.

Pharmacokinetics

Has not been studied.

Clinical characteristics

Indications
As part of the complex therapy of cerebral edema of traumatic, non-traumatic and postoperative genesis, including with intracranial hemorrhages, increased intracranial pressure and edema-swelling phenomena.

Edema of the spinal cord of traumatic, non-traumatic, postoperative genesis.

CSF-venous disorders in chronic cerebrovascular accidents (CVD) and vegetative-vascular dystonia.

Swelling of soft tissues with the involvement of the musculoskeletal system, accompanied by local disorders of their blood supply and pain syndrome; edematous pain syndromes of the spine, extremities; severe violations of the venous circulation of the lower extremities in acute thrombophlebitis, accompanied by an edematous-inflammatory syndrome.

L-lizine Contraindications
Hypersensitivity to the escin salt of 2,6-diaminohexanoic acid and / or other components of the drug;

active continuation of bleeding, which is accompanied by unstable hemodynamics;

severe renal dysfunction;

severe liver dysfunction.

Interaction with other medicinal products and other types of interactions.

When treating L-lysine with escinat, it is possible to prescribe other drugs if indicated (anti-inflammatory, analgesic, antimicrobial).

The drug should not be used simultaneously with aminoglycosides because of the possibility of increasing their nephrotoxicity. In the case of long-term anticoagulant therapy, which was carried out before the appointment of L-lysine aescinat, or if it is necessary to simultaneously use L-lysine aescinat and anticoagulants, the dose of the latter should be adjusted (reduce the dose) and the prothrombin index should be monitored.

The binding of escin to plasma proteins is hampered by the simultaneous use of cephalosporin antibiotics, which can increase the concentration of free escin in the blood with the risk of developing side effects of the latter.